Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City
Picard Medical (NYSE American: PMI) will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Picard Medical (NYSE American: PMI) will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Patrick NJ Schnegelsberg, CEO of Picard Medical, will be available for one-on-one investor meetings; investors should contact their Canaccord Genuity sales representative to schedule a meeting with management.
Details
News Market Reaction – PMI
On Nov 12, the day this news came out, PMI closed 4.53% below the previous close.
Data tracked by StockTitan Argus for the Nov 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY.
Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., will be available for one-on-one meetings with investors; to schedule a meeting, please contact your CG sale representative to set up a meeting with management.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.